Tumor-directed IL-2 variant immunocytokine polytherapy and antibodies to human PD-L1
- 专利权人:
- F. Hoffmann-La Roche AG
- 发明人:
- UMANA, Pablo,KLEIN, Christian,NICOLINI, Valeria G.
- 申请号：
- ES15753700
- 公开号：
- ES2774380T3
- 申请日:
- 2015.08.25
- 申请国别(地区):
- ES
- 年份:
- 2020
- 代理人:
- 摘要：
- The present invention relates to the combination therapy of specific tumor-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- KOMBINIRANA TERAPIJA ZA IMUNOCITOKINE VARIJANTE IL-2 USMJERENE NA TUMOR I PROTUTIJELA PROTIV HUMANOG PD-L1
- THERAPIE COMBINATOIRE D'IMMUNOCYTOKINES A VARIANT DE L'IL -2 CIBLEES THERAPIE TUMORALE ET D'ANTICORPS ANTI-PD-L1 HUMAINE
- Combination therapy with tumor-targeted IL-2 immunocytokine variants and antibodies against human PD-L1
- Kombinirana terapija z imunocitokini različice IL-2, usmerjenimi proti tumorju in protitelesi proti humanemu PD-L1
- TERAPÊUTICA COMBINADA DE IMUNOCITOCINAS DE VARIANTE DE IL-2 DIRIGIDAS AO TUMOR E ANTICORPOS CONTRA PD-L1 HUMANO
